Development and validation of an HPLC method for the impurity and quantitative analysis of etoricoxib

被引：25

作者：

Hartman, R ^{[1
]}

Abrahim, A ^{[1
]}

Clausen, A ^{[1
]}

Mao, B ^{[1
]}

Crocker, LS ^{[1
]}

Ge, ZH ^{[1
]}

机构：

[1] Merck Res Labs, Analyt Res, Rahway, NJ 07065 USA

来源：

JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES | 2003年 / 26卷 / 15期

关键词：

etoricoxib; NSAID; HPLC-MS; validation; stability-indicating;

D O I：

10.1081/JLC-120023800

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Etoricoxib (5-chloro-6'-methyl-3[4-(methanesulfonyl)phenyl]-2,3'-bipyridine) is a highly active and selective cyclo-oxygenase II inhibitor. A single, stability-indicating HPLC method has been developed and validated for both the impurity and quantitative analysis of etoricoxib. Method development incorporated the optimization of stationary phase, pH, temperature, and mobile phase composition for the resolution of thirteen process impurities and three major degradation products. Further optimization of pH and mobile phase composition was aided by the use of DryLab(R), a computer-based simulation program. The stability-indicating capability of the method was proven through the identification of photolytic and oxidative decomposition products. Method validation produced excellent results for linearity, precision, limit of quantitation and limit of detection, specificity, accuracy, recovery, and robustness. The identities of etoricoxib decomposition products were confirmed by UV, LC/MS, and NMR spectra.

引用

收藏

页码：2551 / 2566

页数：16

相关论文

共 22 条

[1] GASTROINTESTINAL DAMAGE ASSOCIATED WITH THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS [J].

ALLISON, MC ;

HOWATSON, AG ;

TORRANCE, CJ ;

LEE, FD ;

RUSSELL, RI .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (11) :749-754

[2] Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors [J].

Bosch, J ;

Roca, T ;

Catena, JL ;

Llorens, O ;

Pérez, JJ ;

Lagunas, C ;

Fernández, AG ;

Miquel, I ;

Fernández-Serrat, A ;

Farrerons, C .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (15) :1745-1748

[3] Nonsteroidal antiinflammatory agents [J].

Botting, JH .

DRUGS OF TODAY, 1999, 35 (4-5) :225-235

[4] In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663) [J].

Chauret, N ;

Yergey, JA ;

Brideau, C ;

Friesen, RW ;

Mancini, J ;

Riendeau, D ;

Silva, J ;

Styhler, A ;

Trimble, LA ;

Nicoll-Griffith, DA .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (08) :1059-1062

[5] Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs [J].

Cryer, B ;

Feldman, M .

AMERICAN JOURNAL OF MEDICINE, 1998, 104 (05) :413-421

[6] An efficient preparation of vinamidinium hexafluorophosphate salts [J].

Davies, IW ;

Marcoux, JF ;

Wu, J ;

Palucki, M ;

Corley, EG ;

Robbins, MA ;

Tsou, N ;

Ball, RG ;

Dormer, P ;

Larsen, RD ;

Reider, PJ .

JOURNAL OF ORGANIC CHEMISTRY, 2000, 65 (15) :4571-4574

[7] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC COMPUTER-SIMULATION BASED ON A RESTRICTED MULTIPARAMETER APPROACH .1. THEORY AND VERIFICATION [J].

DOLAN, JW ;

LOMMEN, DC ;

SNYDER, LR .

JOURNAL OF CHROMATOGRAPHY, 1990, 535 (1-2) :55-74

[8] 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines:: Selective and orally active cyclooxygenase-2 inhibitors [J].

Friesen, RW ;

Brideau, C ;

Chan, CC ;

Charleson, S ;

Deschênes, D ;

Dubé, D ;

Ethier, D ;

Fortin, R ;

Gauthier, JY ;

Girard, Y ;

Gordon, R ;

Greig, GM ;

Riendeau, D ;

Savoie, C ;

Wang, ZY ;

Wong, E ;

Visco, D ;

Xu, LJ ;

Young, RN .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (19) :2777-2782

[9]

GLINKA J, 1978, POL J CHEM, V52, P1039

[10]

GLINKA J, 1977, ROCZ CHEM, V51, P577